These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12867285)

  • 1. Direct observation of 3-keto-valproate in urine by 2D-NMR spectroscopy.
    Meshitsuka S; Koeda T; Muro H
    Clin Chim Acta; 2003 Aug; 334(1-2):145-51. PubMed ID: 12867285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary excretion and metabolism of miglustat and valproate in patients with Niemann-Pick type C1 disease: One- and two-dimensional solution-state (1)H NMR studies.
    Probert F; Ruiz-Rodado V; Zhang X; te Vruchte D; Claridge TD; Edgar M; Tocchio AZ; Lachmann RH; Platt FM; Grootveld M
    J Pharm Biomed Anal; 2016 Jan; 117():276-88. PubMed ID: 26397207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylated metabolites in urine: proton nuclear magnetic resonance spectroscopic study on patients with inborn errors of metabolism.
    Engelke UF; Liebrand-van Sambeek ML; de Jong JG; Leroy JG; Morava E; Smeitink JA; Wevers RA
    Clin Chem; 2004 Jan; 50(1):58-66. PubMed ID: 14633929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volume-selective 1H MR spectroscopy for in vivo detection of valproate in patients with epilepsy.
    Seyfert S; Bernarding J; Braun J
    Neuroradiology; 2003 May; 45(5):295-9. PubMed ID: 12669157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients.
    Kondo T; Tokinaga N; Suzuki A; Ono S; Yabe H; Kaneko S; Hirano T
    Pharmacol Toxicol; 2002 Mar; 90(3):135-8. PubMed ID: 12071334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic drug monitoring of valproate].
    Bentué-Ferrer D; Tribut O; Verdier MC;
    Therapie; 2010; 65(3):233-40. PubMed ID: 20699076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid intoxication identified by 1H and 1H-(13)C correlated NMR spectroscopy of urine samples.
    Azaroual N; Imbenotte M; Cartigny B; Leclerc F; Vallée L; Lhermitte M; Vermeersch G
    MAGMA; 2000 Jul; 10(3):177-82. PubMed ID: 10873209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary excretion of valproate and some metabolites in chronically treated patients.
    Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
    Ther Drug Monit; 1989; 11(2):127-33. PubMed ID: 2497561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo 1H magnetic resonance spectroscopy of rat brain after valproate administration.
    Leib J; Braun J; Schilling A; Klingner C; Seyfert S; Vollmann W; Gedat E; Bernarding J
    Neuroradiology; 2004 May; 46(5):363-7. PubMed ID: 15045495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in clearance of sodium valproate with changes in dose.
    Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
    Clin Exp Neurol; 1987; 24():97-103. PubMed ID: 3151881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta-Ureidopropionase deficiency: a novel inborn error of metabolism discovered using NMR spectroscopy on urine.
    Moolenaar SH; Göhlich-Ratmann G; Engelke UF; Spraul M; Humpfer E; Dvortsak P; Voit T; Hoffmann GF; Bräutigam C; van Kuilenburg AB; van Gennip A; Vreken P; Wevers RA
    Magn Reson Med; 2001 Nov; 46(5):1014-7. PubMed ID: 11675655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration.
    Stockis A; Sargentini-Maier ML; Brodie MJ
    Epilepsy Res; 2016 Dec; 128():163-168. PubMed ID: 27842261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate in the treatment of epilepsy in people with intellectual disability.
    Friis ML
    J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():32-5. PubMed ID: 10030429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of valproic acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency.
    Shinka T; Ohfu M; Hirose S; Kuhara T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 792(1):99-106. PubMed ID: 12829002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DQF J-RES NMR: Suppressing the singlet signals for improving the J-RES spectra from complex mixtures.
    Singh U; Baishya B
    J Magn Reson; 2019 Apr; 301():19-29. PubMed ID: 30844690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of the carbamazepine-valproate interaction in humans.
    Bernus I; Dickinson RG; Hooper WD; Eadie MJ
    Br J Clin Pharmacol; 1997 Jul; 44(1):21-7. PubMed ID: 9241092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate metabolism during hepatotoxicity associated with the drug.
    Eadie MJ; McKinnon GE; Dunstan PR; MacLaughlin D; Dickinson RG
    Q J Med; 1990 Dec; 77(284):1229-40. PubMed ID: 2290919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate.
    Genton P
    Acta Neurol Scand Suppl; 2005; 182():26-32. PubMed ID: 16359430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The scope and use of valproate in epilepsy.
    Penry JK; Dean JC
    J Clin Psychiatry; 1989 Mar; 50 Suppl():17-22. PubMed ID: 2494154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.